PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFosaprepitant
Fosaprepitant
Emend, Focinvez, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant) is a small molecule pharmaceutical. Fosaprepitant was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
emendNew Drug Application2022-05-04
focinvezNew Drug Application2025-07-22
fosaprepitantANDA2025-07-09
fosaprepitant dimeglumineANDA2024-08-15
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC
2025-05-02D-186
Patent Expiration
Patent
Expires
Flag
FDA Information
Fosaprepitant Dimeglumine, Focinvez, Steriscience
110652652039-01-11DP
ATC Codes
No data
HCPCS
Code
Description
J1453
Injection, fosaprepitant, 1 mg
J1456
Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg
Clinical
Clinical Trials
181 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839R11.1932392120117
NauseaD009325R11.042833172199
Postoperative nausea and vomitingD020250EFO_000488824712933
NeoplasmsD009369C803452618
Breast neoplasmsD001943EFO_0003869C50114218
PruritusD011537L2913116
LymphomaD008223C85.912136
LeukemiaD007938C952125
Healthy volunteers/patients314
SyndromeD0135771124
Show 6 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277C80.01214
AlcoholismD000437EFO_0003829F10.133
Marijuana abuseD002189EFO_0007191F12123
Myelodysplastic syndromesD009190D46123
PreleukemiaD011289123
SarcomaD012509112
Germ cell and embryonal neoplasmsD009373112
Pancreatic neoplasmsD010190EFO_0003860C25112
Colorectal neoplasmsD015179112
Myeloid leukemia acuteD015470C92.022
Show 24 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2033
Opioid-related disordersD009293EFO_0005611F1122
Heroin dependenceD006556EFO_000424022
Wounds and injuriesD014947T14.811
Traumatic brain injuriesD000070642S0611
Brain injuriesD001930S06.911
Intracranial hypertensionD019586EFO_100099211
Tobacco use disorderD014029F1711
Head and neck neoplasmsD00625811
Non-hodgkin lymphomaD008228C85.911
Show 2 more
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFosaprepitant
INNfosaprepitant
Description
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Classification
Small molecule
Drug classphosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB
CAS-ID172673-20-0
RxCUI
ChEMBL IDCHEMBL1199324
ChEBI ID64321
PubChem CID219090
DrugBankDB06717
UNII ID6L8OF9XRDC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
No data
Financial
Revenue by drug
$
£
Emend Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 719 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,645 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use